M acrophages govern the immune landscape of many cancers and are key proponents of tumor growth 1 . However, macrophages can also enact antitumor functions. These opposing roles are explained by the phenotypic polarity of macrophages, which are often classified as either pro-inflammatory M1 macrophages that enforce antitumor immunity or immunosuppressive M2 macrophages that promote tumor progression 2 . While macrophages most commonly adopt a phenotype that is supportive of tumor growth 3 , their biology is pliable. As a result, under the appropriate conditions, macrophages can be redirected with antitumor activity 4-6 . The mechanisms that determine pro-versus antitumor functions of macrophages, however, are still being elucidated.
M acrophages govern the immune landscape of many cancers and are key proponents of tumor growth 1 . However, macrophages can also enact antitumor functions. These opposing roles are explained by the phenotypic polarity of macrophages, which are often classified as either pro-inflammatory M1 macrophages that enforce antitumor immunity or immunosuppressive M2 macrophages that promote tumor progression 2 . While macrophages most commonly adopt a phenotype that is supportive of tumor growth 3 , their biology is pliable. As a result, under the appropriate conditions, macrophages can be redirected with antitumor activity [4] [5] [6] . The mechanisms that determine pro-versus antitumor functions of macrophages, however, are still being elucidated.
One mechanism governing pro-and antitumor roles of macrophages is the balance of stimulatory and inhibitory signals. For example, a key negative regulator of macrophage activity is CD47, a membrane-bound protein overexpressed by many cancers 7, 8 . CD47 is a 'don't-eat-me' signal that suppresses the phagocytic activity of macrophages on binding SIRPα (signal regulatory protein α )receptor present on phagocytes 9 . Blocking CD47-SIRPα binding promotes macrophage engulfment of tumor cells and induces antitumor responses in multiple xenograft models 7, 10 . However, in models of pancreatic ductal adenocarcinoma (PDAC), CD47blockade as a monotherapy has shown modest antitumor efficacy 11 , which may be explained by the limited pro-phagocytic effect of CD47-blockade seen in non-hematopoietic tumor models 12 . These findings suggest that additional stimuli are required to potentiate antitumor activity by macrophages.
Macrophage stimulation is directed by cytokines and agonists of pathogen recognition receptors, such as Toll-like receptors (TLRs), which together determine macrophage phenotype 13 . Unique combinations of stimuli have been used in vitro to define classical phenotypic states of macrophages, such as M1 and M2. However, in pathological settings, such as cancer, macrophages more commonly acquire phenotypes that span a spectrum of differentiation states 14, 15 .
When examined using systems-based approaches, macrophage phenotypes can be distinguished by their core metabolic processes 15, 16 . For example, M1 macrophages rely on glycolytic metabolism and reduced oxidative phosphorylation, whereas M2 macrophages perform de novo lipogenesis and glutaminolysis to support fatty acid oxidation (FAO) [17] [18] [19] . Additional studies support an association between M2-macrophage polarity and FAO, but indicate that these can also occur independently 20 . In particular, FAO and lipid metabolism underpin the antitumor functions of multiple myeloid subsets (for example dendritic cells and myeloid-derived suppressor cells) [21] [22] [23] . Similarly, lipid availability can modulate macrophage engulfment of red blood cells and macromolecules 24, 25 . Together, these findings underscore the potential role of metabolism in defining myeloid cell biology and suggest that lipid metabolism may likewise coordinate macrophage function in cancer.
To understand the metabolic determinants that govern macrophage antitumor function, we used metabolomic approaches and a syngeneic model of PDAC to study macrophage engulfment of PDAC cells on TLR stimulation. Further, we leveraged targeted knockout of CD47 in PDAC cells to understand how macrophage activation acts together with inhibition of anti-phagocytic signals present in cancer. Our studies reveal a novel role for metabolic pathways in regulating macrophage antitumor functions and underscore the potential of targeting macrophage metabolism for overriding Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47−mediated 'don't-eat-me' signal Mingen Liu 1 , Roddy S. O'Connor 2 , Sophie Trefely 3,4 , Kathleen Graham 1 , Nathaniel W. Snyder 3 and Gregory L. Beatty 1,5 * Macrophages enforce antitumor immunity by engulfing and killing tumor cells. Although these functions are determined by a balance of stimulatory and inhibitory signals, the role of macrophage metabolism is unknown. Here, we study the capacity of macrophages to circumvent inhibitory activity mediated by CD47 on cancer cells. We show that stimulation with a CpG oligodeoxynucleotide, a Toll-like receptor 9 agonist, evokes changes in the central carbon metabolism of macrophages that enable antitumor activity, including engulfment of CD47 + cancer cells. CpG activation engenders a metabolic state that requires fatty acid oxidation and shunting of tricarboxylic acid cycle intermediates for de novo lipid biosynthesis. This integration of metabolic inputs is underpinned by carnitine palmitoyltransferase 1A and adenosine tri-phosphate citrate lyase, which, together, impart macrophages with antitumor potential capable of overcoming inhibitory CD47 on cancer cells. Our findings identify central carbon metabolism to be a novel determinant and potential therapeutic target for stimulating antitumor activity by macrophages.
Tumor-associated macrophages are essential for CpG-activated antitumor responses. We next evaluated the in vivo antitumor activity of CpG on established murine PDAC tumor growth. Treatment was initiated with intraperitoneal injection of vehicle (PBS) or CpG on day 10 with repeated administration every other day for a total of five doses ( Fig. 2a ). CpG treatment potently suppressed tumor growth in two independent PDAC tumor models ( Fig. 2b,c) . Although tumors ultimately relapsed, CpG significantly prolonged overall survival ( Fig. 2d ) without inducing gross toxicity or lethality. This effect was also independent of any direct cytotoxic activity of CpG on tumor cells, as treatment of PDAC cells in vitro with supratherapeutic concentrations of CpG did not affect tumor cell survival ( Supplementary Fig. 2 ).
Repeated dosing of CpG to non-tumor-bearing mice has been found to stimulate a macrophage-activation syndrome 28 . Therefore, we examined the impact of treatment on the systemic release of inflammatory cytokines. We found that in vivo delivery of CpG to tumor-bearing mice increased pro-inflammatory cytokines in the serum, including TNF, IFN-γ and CCL2 ( Fig. 2e ). Consistent with this increase in inflammatory and chemotactic factors, we observed an increase in tumor-associated macrophages following CpG treatment ( Fig. 3a,b ). In addition, we detected an increase in F4/80 + macrophage phagocytosis of tumor cells in CpG-treated tumors ( Supplementary Fig. 3 ). To ascertain the role of tumorassociated macrophages in the response to CpG treatment, we depleted distinct macrophage populations using GW2580, an inhibitor of colony stimulating factor 1-receptor (CSF1Ri), and CEL, which target phagocytes residing outside of the tumor microenvironment 29 . Depletion with either CEL or CSF1Ri alone did not affect tumor outgrowth in the vehicle-treated groups (Fig. 3c ). In contrast, CSF1Ri abrogated the antitumor effect of CpG, whereas CEL did not ( Fig. 3c ). Similarly, we found that administration of an anti-CSF1R antibody attenuated the CpG-induced antitumor response ( Fig. 3d ). These findings implicated a CSF1R + population of macrophages, which are not targeted by liposomes, in mediating the antitumor response by CpG. Consistent with this observation, we found that CEL did not alter macrophage presence within tumors ( Fig. 3a ), whereas both CSF1Ri (Fig. 3a,b ) and anti-CSF1R antibody ( Fig. 3e ) treatment decreased the abundance of tumorassociated macrophages.
To ascertain the possible contribution of other immune effectors, we considered a role for lymphocytes in CpG-induced antitumor activity. We found that CpG did not significantly alter the infiltration of T cell subsets (CD8 + , CD4 + and CD4 + Foxp3 + ) into tumors (data not shown). In addition, we detected no significant change in the expression of immune regulatory markers, including PD-1 and Tim3, by T cells after CpG treatment (data not shown). CpG-induced antitumor activity was also preserved in Rag2deficient mice bearing PDAC.1 tumors, thereby excluding a role for lymphocytes ( Supplementary Fig. 4a ). Antitumor activity induced with CpG was also preserved in mice depleted of natural killer cells using the anti-NK1.1 antibody ( Supplementary Fig. 4b ). In addition, we found that depletion of dendritic cells using the CD11c-DTR-eGFP mouse model did not alter the antitumor response stimulated by CpG ( Supplementary Fig. 4c ). Collectively, these data indicate that T and B lymphocytes as well as dendritic cells and natural killer cells are not required for the antitumor response induced by CpG.
We have previously shown a role for peripheral blood myeloid cells in mediating antitumor activity against PDAC 4 . Thus, we investigated the expression of CSF1R on myeloid cell populations in the peripheral blood. We found that CSF1R was expressed by a subset of CD11b + F4/80 + myeloid cells bearing high levels of the monocyte marker Ly6C (data not shown), which marks a population of myeloid cells that have been previously shown to be recruited to PDAC tumors 4, 30 . Further, administration of an anti-CSF1R antibody significantly reduced the Ly6C hi myeloid population in the peripheral blood (data not shown). We also found, similar to CSF1Ri and anti-CSF1R treatment, that anti-Ly6C antibodies, which deplete the Ly6C hi monocyte population Articles NATure IMMuNOlOGy in vivo 4 , blocked both the accumulation of F4/80 + macrophages in tumors ( Fig. 3f ) and the CpG-induced antitumor response ( Fig. 3g ). Together, these data implicate myeloid cells marked by expression of Ly6C and CSF1R in the antitumor activity induced by CpG 31 .
CpG activation of macrophages bypasses inhibitory CD47 on PDAC cells.
We next sought to understand the mechanism by which CpG stimulates macrophages with enhanced phagocytic and antitumor activity. We considered that CpG might alter the capacity of macrophages to respond to CD47 as a negative regulatory signal. To test this, we assessed the impact of CpG on SIRPα expression. However, we observed no changes in SIRPα surface expression with increasing duration of CpG activation (Fig. 4a ). We also examined the effect of CpG activation on macrophage-inhibitory signals present in vitro. We found that CpG-BMDMs phagocytosed PDAC cells that either expressed or lacked CD47, indicating that CpG stimulates macrophages with antitumor activity that is independent, at least in part, of CD47 as a macrophage-inhibitory signal (Fig. 4b ). This finding was generalizable as CpG activation enabled macrophage engulfment of CD47-expressing syngeneic tumor cells derived from breast cancer, melanoma, colorectal cancer, glioblastoma, lung cancer and lymphoma ( Fig. 4c ). CD47-blockade alone also showed limited capacity to enhance macrophage phagocytosis in these tumors, except for EL4 lymphoma cells. However, despite limited activity by itself, we found that genetic ablation of CD47 in tumor cells ( Fig. 4b ) as well as CD47-blockade ( Fig. 4c ) significantly enhanced the capacity of CpG-stimulated macrophages to phagocytose tumor cells in vitro, implying that appropriate macrophage-activation signals are critical for overcoming CD47 in nonhematopoietic tumors.
Previous studies have suggested that TLR agonists might promote phagocytic and antitumor activity by stimulating macrophages to produce calreticulin 32 . To test this possibility, we quantified calreticulin expression-including both membrane-bound and intracellular levels-but detected no differences between mock-BMDMs and CpG-BMDMs ( Supplementary Fig. 5 ). Further, on extended co-culture, CpG-BMDMs effectively eliminated PDAC cells, with loss of CD47 expression in tumor cells providing an additive benefit in antitumor activity ( Fig. 4d ). However, the ability of CpG to 
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NATure IMMuNOlOGy promote antitumor activity by macrophages despite CD47 expression on tumor cells is in contrast with other TLR agonists, for which blockade of CD47 is critical for macrophage activity 32 .
We then asked whether disruption of CD47 enhances the in vivo antitumor activity of macrophages. Delivery of CpG to mice bearing control or CD47 knockout (Cd47 −/− ) tumors produced similar 
NATure IMMuNOlOGy increases in the relative abundance of tumor-associated macrophages ( Fig. 4e,f) . The impact of CpG on tumor growth was also similar in tumors that expressed or lacked CD47 (Fig. 4g ). These findings underscore the dominant response elicited by CpG activation of macrophages in vivo that can overcome CD47 expressed by PDAC cells.
CpG induces a shift in macrophage metabolism. Microenvironmental cues can induce distinct phenotypes in macrophages. For example, the combination of LPS and IFN-γ promote an M1 phenotype in macrophages, which is associated with pro-inflammatory and antitumor activity in cancer 1, 2 . In contrast, the combination of IL-4 and IL-13 endows macrophages with M2-polarity, which suppresses inflammation and promotes tumor growth. To study the direct effect of CpG on macrophage polarity, we evaluated CpG-BMDMs for markers associated with M1 and M2 macrophages, including arginase 1 (Arg1), CD206, MHC-II, inducible nitric oxide synthase (iNOS), IL-6 and IL-12 33 . We found that CpG activation increased the expression of both iNOS and Arg1, which are associated with M1(LPS) and M2(IL-4) macrophages, respectively ( Fig. 5a ). However, CpG did not significantly alter expression of MHC-II or CD206, markers increased by M1(LPS) and M2(IL-4) polarization, respectively ( Fig. 5b ). CpG also induced production of both proinflammatory cytokines (that is, IL-6, IL-12, CCL2 and TNF) and anti-inflammatory cytokines (that is, IL-10) relative to mock-treatment ( Fig. 5c ). Further examination of additional markers revealed that CpG did not modulate IL-4R alpha, CD80 or CD86, but upregulated expression of Fcγ RIII and PD-L1 (data not shown). 
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Pro-inflammatory stimuli can also alter macrophage metabolism 15, 34 . Therefore, we sought to understand the impact of CpG activation on the metabolic state of macrophages by assessing their ECAR (extracellular acidification rate) and OCR (oxygen consumption rate). We found that CpG and several other TLR agonists increased ECAR relative to mock-BMDMs, indicating an increase in glycolytic flux ( Fig. 5d and Supplementary Fig. 6 ). However, distinct from other TLR agonists, CpG elevated the basal OCR of macrophages, signifying higher rates of oxidative phosphorylation (Fig. 5e,f and Supplementary Fig. 6 ). This metabolic change seen in CpG-stimulated macrophages is consistent with metabolic activation seen in dendritic cells in response to CpG 35 . Further, we observed that the basal OCR of macrophages increased with prolonged CpG stimulation ( Fig. 5g ) and corresponded with reduced spare respiratory capacity ( Fig. 5h ). Collectively, these findings demonstrate that CpG activation confers a unique metabolic shift in macrophages and that CpGactivated macrophages do not fully conform to the classical M1(LPS) or M2(IL-4) classification.
Lipid metabolism is critical for antitumor functions induced by CpG. We next investigated the significance of elevated oxygen consumption in response to CpG activation by first assessing mitochondrial abundance in macrophages. CpG-BMDMs exhibited an increase in total mitochondria, in comparison to mock-BMDMs ( Supplementary Fig. 7a ). To further evaluate changes in mitochondrial function, we tested the contribution of FAO toward elevated oxygen consumption under normal culture conditions, in the presence of serum and without other exogenous lipids. FAO was restricted using etomoxir, an irreversible inhibitor of the enzyme carnitine palmitoyltransferase 1A (CPT1A) that is involved in fatty acid breakdown. We found that FAO inhibition blocked the CpGinduced increase in macrophage OCR without affecting the maximal respiratory capacity ( Fig. 6a,b ). Furthermore, FAO inhibition with etomoxir attenuated the capacity of CpG-BMDMs to phagocytose PDAC cells, whether they expressed inhibitory CD47 or not ( Fig. 6c,d) .
To test the role of FAO for the in vivo antitumor activity induced by CpG, etomoxir was administered daily to mice beginning on 
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NATure IMMuNOlOGy day 9 before initiating CpG treatment on day 10. We found that etomoxir treatment blocked the antitumor effect of CpG, whereas treatment with etomoxir alone had no significant effect on tumor outgrowth ( Fig. 6e ). Importantly, etomoxir treatment also did not alter the abundance of F4/80 + macrophages in the tumor microenvironment, indicating that the inhibitory effect observed was not a result of depletion or exclusion of macrophages from the tumor microenvironment ( Fig. 6f) . Rather, the inhibitory effect of etomoxir was associated with decreased engulfment of tumor cells by F4/80 + macrophages ( Supplementary Fig. 3 ). Together, these data demonstrate a key role for FAO in macrophage-dependent antitumor activity induced with CpG.
De novo lipogenesis, but not exogenous fatty acids, are critical for CpG-activated antitumor activity. To define the metabolic changes induced by CpG, we assessed the abundance of short chain coenzyme A (CoA) species in mock-and CpG-treated macrophages. We considered that an increase in FAO in CpG-BMDMs would require breakdown and incorporation of exogenous fatty acids into acetyl-CoA and tricarboxylic acid (TCA) substrates. Surprisingly, we found that the incorporation of labeling from 13 C-palmitate into acetyl-CoA and succinyl-CoA was decreased in CpG-BMDMs, indicating that substrates other than exogenous palmitate probably serve as precursors for generating acetyl-CoA and succinyl-CoA in response to CpG stimulation (Fig. 7a,b ). We next investigated the impact of CpG on increased fatty acid uptake, which is a key feature of M2 macrophages. We found that CpG-BMDMs did not upregulate fatty acid transporters such as CD36 that instead was significantly downregulated in response to CpG stimulation ( Supplementary  Fig. 7b ). In addition, CpG-BMDMs showed a limited increase in the uptake of boron-dipyrromethene-(BODIPY-)labeled palmitate, indicating that utilization of exogenous fatty acids was not significantly altered in macrophages by CpG stimulation ( Supplementary  Fig. 7c ). Together, these findings illustrate that while CpGmacrophages share several metabolic features with M2 macrophages, such as their oxidative phenotype, they differ significantly in their use of exogenous fatty acids. We proceeded to examine alternative pathways that may support metabolic activation in CpG-BMDMs. On substitution of glucose or glutamine with 13 C-glucose or 13 C-glutamine in the media, the relative total pool sizes for acetyl-CoA, succinyl-CoA and HMG (hydroxymethylglutaryl)-CoA increased in CpG-BMDMs compared to mock-BMDMs (Fig. 7c ). The percentage of acetyl-CoA derived from glucose (M + 2 isotopologue) increased 
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in CpG-BMDMs relative to mock-BMDMs (Fig. 7d ). This shift was accompanied by a decreased percentage of acetyl-CoA derived from glutamine (M + 2 isotopologue) in CpG-BMDMs (Fig. 7d) . Conversely, incorporation of 13 C-glucose into succinyl-CoA (M + 4 isotopologue) decreased on CpG stimulation, and was accompanied by an increase in labeled, glutamine-derived succinyl-CoA (M + 4 isotopologue) in CpG-BMDMs compared to mock-BMDMs (Fig. 7e ). Together, these data show that CpG activation of macrophages promotes a shift away from complete utilization of carbon from glucose and toward glutamine anaplerosis for generating TCA cycle intermediates such as succinyl-CoA. The incorporation of glucose into acetyl-CoA and HMG-CoA (a precursor for the cholesterol synthesis pathway) seen in CpGstimulated BMDMs was consistent with a shunting by adenosine tri-phosphate citrate lyase (ACLY) and de novo biosynthesis of cholesterol and/or lipids 16 . Lipid metabolism can impact multiple biological processes in macrophages, including cellular organelle production, cytokine secretion and lipid membrane properties 36, 37 . Therefore, we examined a role for secretory capacity in CpG-induced macrophage phagocytosis. We found that blocking endoplasmic reticulum secretion using brefeldin A inhibited CpG-induced phagocytosis of tumor cells ( Supplementary Fig. 7d ). This finding was consistent with previous work showing a role for the endoplasmic reticulum as a source of membrane for phagocy-tosis 38 . Therefore, we next hypothesized that disruption of ACLY would alter membrane properties and directly impede the antitumor activity of CpG-activated macrophages. We found that inhibition of ACLY during CpG-induced macrophage activation attenuated the oxidative phenotype (Fig. 7f ) and reversed membrane fluidity ( Supplementary Fig. 7e ), an established regulator of macrophage phagocytosis. Consistent with this, we also found that inhibition of ACYL abrogated the antitumor phagocytic activity of CpG-stimulated macrophages even with combined CD47 ablation (Fig. 7g ). Together, our findings demonstrate that CpG imparts macrophages with a unique metabolic state, defined by enhanced oxidative phosphorylation and a shunting of TCA cycle intermediates, which determines their antitumor potential and capacity to circumvent inhibitory signals received by CD47 expressed on malignant cells.
Discussion
Macrophages dominate the microenvironment of many cancers, wherein they are directed toward a pro-tumor role and restricted in their antitumor potential. The capacity of macrophages to engulf and kill tumor cells is countervailed by their phenotype as well as inhibitory signals present within their surrounding microenvironment, including the anti-phagocytic molecule CD47, which is overexpressed by malignant cells 7, 8 . Our study identifies the central 
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NATure IMMuNOlOGy carbon metabolism of macrophages as a regulator of their antitumor functions, including the capacity to phagocytose tumor cells. We found that redirection of macrophages toward an oxidative phenotype is essential for antitumor activity induced by CpG stimulation in vitro and in vivo. CpG-stimulated alterations in macrophage metabolism were necessary for circumventing inhibitory signals mediated by CD47. Together, our findings highlight rewiring macrophage metabolism-by promoting FAO and redirecting the use of TCA intermediates-as a mechanism to circumvent negative regulatory signals present on malignant cells and to endow macrophages with antitumor potential.
Inhibitory signals expressed by tumor cells may not always be dominant in regulating antitumor activity by macrophages. Unlike findings in other cancers, we found that disruption of CD47 activity via antibody blockade was not sufficient for inciting antitumor responses in an immunocompetent tumor model of PDAC. Deletion of tumor-expressed CD47 was also not sufficient for inducing in vitro phagocytosis of tumor cells or in vivo antitumor responses. The absence of macrophage activity in this setting was not due to a lack of pro-phagocytic signals as treatment with CD47-blocking antibodies, which contain Fc-domains for driving Fc receptor dependent pro-phagocytic signals in macrophages, also failed to elicit macrophage antitumor activity in vitro and in vivo. Further, in the absence of macrophage activation via CpG stimulation, we found that CD47-blocking antibodies were insufficient for stimulating macrophage phagocytosis of multiple solid tumor types including colorectal, glioblastoma, melanoma, breast cancer and lung cancer. Our data support a conceptual model in which inhibitory signals, such as CD47, can be overcome by the activation state of macrophages, which is defined by core metabolic pathways that govern their antitumor potential. Consistent with this, we observed a notable role for CD47 in regulating macrophage antitumor activity in vitro, but only when macrophages were activated with CpG, which provides rationale for combining CD47 antagonists with myeloid agonists. However, this finding was not appreciated in vivo where CpG-induced antitumor activity was indistinguishable between tumors that expressed or lacked CD47. This may reflect the emergence of additional anti-phagocytic signals that are redundant with CD47 expressed by tumor cells 39 or even the capacity of CpG to more effectively activate macrophages in vivo to circumvent inhibitory signals mediated by CD47.
The functional consequences of metabolic changes in macrophages has remained poorly defined in cancer, despite findings to suggest that lipid metabolism has a pivotal role in governing the antitumor functions of several other immune cell types (for example, myeloid-derived suppressor cells, dendritic cells and T cells) 21, 22, 40 . We showed that, similar to M1 macrophages, CpG-activated macrophages redirected exogenous fatty acids and glucose toward acetyl-CoA generation and de novo lipid biosynthesis. We also found, as seen in M2 macrophages, that FAO and glutaminolysis were essential for the oxidative phenotype of CpG-activated macrophages 17, 18 . Notably, M2 macrophages are recognized to possess superior abilities than M1 macrophages in phagocytosing antibody-opsonized tumor cells 41 , suggesting an association between FAO and phagocytic capacity. Functionally, FAO in antitumor macrophages may enable the breakdown of large lipid loads after engulfment of target cells or fulfill the metabolic demands for phagocytosis 42 . Together, our findings substantiate the importance of lipid metabolism as a dominant regulator of antitumor activity by macrophages.
Changes in lipid metabolism can alter plasma membrane properties in macrophages and in doing so, confer them with an ability to phagocytose more effectively 25 . Our data show enhancement of membrane fluidity induced by CpG that is dependent on acetyl-CoA shunting for de novo lipogenesis. In turn, membrane fluidity can modulate CD47-SIRPα signaling and receptor clustering at phagocytic synapses 43, 44 . Macrophage activation by TLRs has been shown to promote lipid-modifying programs that alter ceramide and sphingolipid species, which may influence the membrane properties of macrophages 45 . Analogously, CpG activation enhances lipogenesis in macrophages, which consequently modulates secretory function 37, 46 . Consistent with this, we identified secretory pathways between the endoplasmic reticulum and Golgi to be critical for CpG-induced phagocytosis. In non-cancerous settings, lipogenesis supports macrophage engulfment of microparticles, due to its role in phospholipid synthesis and expansion of cellular organelles (for example, endoplasmic reticulum and Golgi) 36 . However, the relevance of de novo lipogenesis for macrophage activity in cancer and for circumventing inhibitory signals of phagocytosis (that is, CD47) has not been previously reported. We find that CpG increases mitochondrial abundance and enhances FAO, along with shunting of acetyl-CoA toward cholesterol biosynthesis. This mechanism is necessary for CpG to endow macrophages with the capacity to phagocytose tumor cells, without need for engaging Fc-receptors or blocking CD47 activity.
Most clinical studies evaluating CpG oligonucleotides have investigated subcutaneous delivery and weekly administration with the goal of stimulating dendritic cells and mobilizing T cell immunity. However, thus far, CpG has demonstrated limited efficacy [47] [48] [49] . In contrast to these studies, we administered CpG systemically and repeatedly to incite robust and sustained macrophage activation. Our data suggest that activation of adaptive immunity may not always be required for CpG-induced antitumor activity and support evaluating the potential of CpG to stimulate macrophage antitumor activity in the clinical setting.
The mechanisms involved in shifting the role of macrophages from pro-to antitumor have remained poorly defined. We found that CSF1R + macrophages were necessary for mounting an antitumor response on CpG activation, despite this subset of macrophages being associated with immunosuppression 50 . Our findings show a role for core metabolic processes, which act together as a key regulator of macrophage antitumor activity. Our findings also highlight the importance of the metabolic state of macrophages for circumventing immune checkpoint signals with implications for broadening the impact of immunotherapy and identify macrophage metabolism as a novel therapeutic target that must be appropriately wired to enable macrophages to carry out antitumor functions.
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Methods
Mice. C57BL/6J, Rag2 −/− (B6(Cg)-Rag2 tm1.1Cgn /J), CD11c-DTR/eGFP (B6.FVB-1700016L21 RikTg(Itgax-DTR/EGFP)57Lan /J) mice were obtained from Jackson Laboratories. CD11c-DTR/eGFP heterozygotes were enrolled in tumor studies. Animal protocols were reviewed and approved by the Institute of Animal Care and Use Committee (IACUC) of the University of Pennsylvania and conducted in compliance with the guidelines for animal research by the National Institutes of Health.
Cell lines. PDAC.1 (152 PDA) and PDAC.2 (69 PDA) cell lines were derived from PDAC tumors, as previously described 4 , which arose spontaneously in Kras LSL.G12D/+ ; Trp53 R172H/+ ; Pdx-Cre mice backcrossed onto the C57BL/6 background (Jackson Labs). Cell line authentication was performed as previously described 4 . Isogenic PDAC lines were established by cloning single cells for in vitro and in vivo experiments. PDAC knockout lines were generated as previously described ( Supplementary Table 3 ): Cell lines from American Type Culture Collection include 4T1 (breast cancer), B16F10 (melanoma), EL4 (T cell lymphoma), GL261 (glioblastoma), LLC (Lewis Lung Carcinoma) and MC38 (colorectal cancer). Cell lines were negative for mycoplasma testing. 1 × 10 6 tumor cells from isogenic lines were transiently transfected with guide RNAs targeting GFP (5′ -GTGAACCGCATCGAGCTGAA-3′ ) or CD47 (5′ -GGAGCCATCCTTCTCATCCC-3′ ) sequences. Guide RNAs were inserted into TOPO-plasmids (Qiagen) per manufacturer instructions, and mixed 1:1 with LentiCRISPR V2 plasmid (Addgene). The plasmid mix was combined with Lipofectamine 2000 (Thermo Scientific Fisher) and Opti-MEM (Thermo Scientific Fisher) for transfection mixture. Tumor cells were transfected for 6 h; at 24 h posttransfection, cells were treated with 1 μ g ml −1 puromycin (Invivogen) for 2 days. Following selection, tumor cells were stained for CD47 and purified as CD47 + and CD47 − populations by fluorescence-activated cell sorting. Reporter cell lines were generated for phagocytosis and antitumor assays by transduction with lentivirus encoding GFP and Click Beetle Green luciferase, joined by a T2A signal peptide. After expansion, GFP-expressing PDAC cells were isolated using fluorescenceactivated cell sorting.
Reagents. TLR agonists were resuspended in PBS (phosphate buffered saline, Thermo Scientific Fisher) before addition to cell culture media at final concentrations of: 1 μ g ml −1 Pam3CSK4 (Invivogen), 1 μ g ml −1 PolyI:C (Invivogen), 1 μ g ml −1 Escherichia coli LPS (Invivogen), 1 μ g ml −1 flagellin (Invivogen), 1 μ g ml −1 imiquimod (Invivogen), 100 μ g ml −1 ODN1826 CpG DNA (Invivogen and Integrated DNA Technologies). Etomoxir (Sigma) was reconstituted in DMSO (Sigma) and supplemented into media at a 200 µ M concentration; BMS 303141 (Tocris) was reconstituted in DMSO and added into media at 50 µ M concentration. Thapsigargin (Sigma) and staurosporine (Sigma) were reconstituted in DMSO and added into media at 10 nM and 1 mM, respectively. Brefeldin A at 5 µ g ml −1 was applied to activated macrophages for 12-24 h before assays. For mock-treatment, PBS or DMSO vehicles were used as controls when appropriate.
Tissue culture. Tumor cells were cultured in DMEM (Dulbecco's Modified Eagle's Media, Thermo Scientific Fisher) supplemented with 10% v/v FCS (fetal calf serum, Gemini and VWR), 2 mM glutamax (Thermo Scientific Fisher) and 10 ng ml −1 gentamicin (Thermo Scientific Fisher). Cell cultures and in vitro cocultures were maintained at 37 °C and 5% CO 2 . Cell counts were determined using a hemacytometer. For in vitro experiments, PDAC cells were below passage 15, and for in vivo experiments, cells were below passage 10.
Generation of BMDMs.
BMDMs were derived by isolating bone marrow from mice euthanized with CO 2 overexposure. Following treatment with ACK lysis buffer (Thermo Scientific Fisher), bone-marrow cells were cultured in Iscove's Modified Eagle's Media (Thermo Scientific Fisher) supplemented with 10% v/v FCS, 2 mM glutamax, 10 ng ml −1 gentamicin and 10 ng ml −1 M-CSF (Peprotech) for 7-10 days. Before use in experiments, BMDMs were removed from M-CSF and pretreated with TLR agonists or inhibitors for indicated durations.
Flow cytometry. Tumor cell cultures were treated with trypsin (Thermo Scientific Fisher) and prepared as a single-cell suspension for flow cytometric analysis; BMDMs in culture were incubated in cell dissociation buffer (Thermo Scientific Fisher) before mechanical detachment and resuspension. For intracellular stains, cells were permeabilized in 0.1% Triton-X (Sigma) for 15 min. For tumors, samples were collected on necropsy, mechanically separated and digested in 1 mg ml -1 collagenase (Sigma) and 100 μ Units per ml DNase I (Roche). Tumor digests were filtered and resuspended as single-cell suspensions. Cells were treated with Fc-block (BD Pharmingen), then stained with Amcyan live/dead dye (Thermo Scientific Fisher). For antibody staining ( Supplementary Table 1 ), cells were washed with PBS containing 2% FCS and stained on ice. Flow analysis was performed using FACS Canto (BD Biosciences), and singlets were gated on using FSC-H versus FSC-A.
BODIPY-C16 labeling. BMDMs were seeded at 1 × 10 5 cells per well into a 96-well plate and stimulated with vehicle or 10 µ g ml −1 CpG for 18 h. Following stimulation, media was replaced with fresh DMEM supplemented with 10% v/v FCS, 2 mM glutamax, 10 ng ml −1 gentamicin and 1 µ g ml −1 BODIPY-C16 (Thermo Scientific Fisher) for 1 h. After labeling, cells were washed, detached and analyzed by flow cytometry on a FACS Canto.
In vitro phagocytosis assay. Pretreated BMDMs were mechanically detached and labeled with 5 μ M DiI (Life Technologies), then seeded into a transparent 96-well tissue culture plate at 5 × 10 4 cells per well. GFP-labeled PDAC cells were gathered as a single-cell suspension and seeded at 5 × 10 4 cells per well. For other tumor cell lines, cell suspensions were labeled with 5 μ M DiO (Life Technologies) and washed before being seeded at 5 × 10 4 cells per well. Following 4-h co-culture, samples were washed and fixed in 4% PFA (paraformaldehyde, Sigma) for 15 min before image collection. For antibody blockade, tumor cell suspensions were incubated with 10 µ g ml −1 isotype (2A3, BioXcell) or rat-anti-mouse anti-CD47 (Miap301, BioXcell) antibodies for 20 min, before being washed and co-incubated with macrophages. Multiple random fields were collected per replicate, using an Olympus IX83 microscope, and the number of phagocytic events were scored and averaged for each replicate.
In vivo phagocytosis. Frozen sections of PDAC tumors were fixed for 20 min in 4% PFA, followed by permeabilization in ice-cold methanol for 20 min. Samples were blocked for 1 h in 10% goat serum and stained for 4 h in primary antibodies (rabbit-anti-mouse cytokeratin 19, rat-anti-mouse F4/80). After washing, secondary antibody (488 goat-anti-rabbit, 568 goat-anti-rat) was applied for 1 h. Samples were washed, and images were captured using an Olympus IX83 microscope. Background reduction was performed in CellSens software (Olympus) and images were subsequently processed using EBImage software analysis in R to perform color deconvolution, adaptive thresholding of F4/80 signal, Gaussian blur and binarization of signal. Size exclusion was applied to remove particles with a radius less than 10 pixels or greater than 200 pixels. The green (CK) signal was normalized intrinsically for each image to minimize variability in staining intensity. The phagocytic index was determined by calculating the normalized green (CK) intensity within each F4/80 + cells.
Antitumor activity assay. Luciferase-labeled PDAC cells were collected as a singlecell suspension and seeded into a 96-well tissue culture plates at 5 × 10 4 cells per well. Pretreated BMDMs were collected by mechanical detachment and seeded at 0:1, 1:1, 2:1 and 5:1 macrophage-to-tumor ratios. After 48-h co-culture, tumor cell survival was determined using Luciferase assay system (Promega). Luminescence measurements were performed using a SpectraMax M3 reader (Molecular Devices). Tumor cell survival was determined by normalizing luminescence to tumor-only controls.
Immunohistochemistry. Cryosectioned murine PDAC tumors were fixed in 4% PFA and treated with 0.1% hydrogen peroxide (Sigma). Samples were blocked in 10% goat serum (Vector Laboratories) in PBS and treated overnight with primary antibodies (Supplementary Table 2 ). Secondary antibody was applied for 1 h, and samples were stained with ABC HRP kit (Vectastain) per manufacturer instructions. Samples were then treated with DAB (3, 3 -diaminobenzidine) HRP substrate (Vector Labs) before counterstaining with hematoxylin (Sigma) and dehydration. Images were captured using the Olympus BX-43 microscope.
Immunofluorescence microscopy. Treated BMDMs were collected by mechanical detachment and seeded into glass chamber slides (Nunc). Samples were then fixed in 4% PFA, permeablized in 0.1% Triton-X for 15 min and blocked with 10% goat serum (Vector Laboratories) in PBS. Primary antibodies and isotype control were applied overnight and washed; secondary antibody was applied for 1 h and washed. Samples were stained with DAPI for 15 min and mounted before image acquisition. Images were captured using the Olympus IX83 microscope.
Membrane fluidity. BMDMs were seeded at 2.5 × 10 5 cells per well in 24-well plates, and stimulated under mock, CpG, CpG + ACLY-inhibitor (BMS 303141) or CpG + etomoxir conditions for 72 h. Samples were then assessed using the membrane fluidity kit (Abcam). After stimulation, plates were washed and labeled with 10 uM pyrenedecanoic acid + 0.08% pluronic F127 for 30 min at 37 °C. Cells were gathered by gentle scraping, washed and analyzed for fluorescence of monomer (400 nm) and excimers (470 nm) using a FACS Canto. Per manufacturer recommendations, membrane fluidity was quantified using the ratio of excimer/ monomer mean fluorescence intensity.
Tumor growth studies. PDAC cells were gathered from culture, washed and prepared as a single-cell suspension for implantation into the subcutis of mice. Rat-anti-mouse anti-CD47 (MIAP301, BioXcell) and isotype control antibodies (2A3, BioXcell) were diluted in saline, and 50 µ g of each antibody was delivered intratumorally on days 10 and 14 after tumor implantation, as previously described ( Supplementary Table 3 ). Tumor-bearing mice were treated with vehicle (PBS) or 50 μ g CpG by intraperitoneal injection every other day, beginning on day 10. For macrophage depletion, 200 μ l of CEL (clodronateliposomes.org) was delivered by retroorbital injection into mice, 400 μ g of anti-CSF1R Ig (AFS98, BioXcell) diluted in saline was delivered by intraperitoneal injection on days 8, 10, 13, 16 or GW2580 1 nature research | reporting summary A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. 
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
Sample sizes were estimated based on pilot experiments, in which control tumors reached an average volume of 300mm3 at day 18 postimplantation, with a sigma of 50mm3. Assuming a medium effect size with treatment (35% tumor size reduction), sample sizes were determined for a two-sided statistical test, with the potential to reject the null hypothesis with a power (1-β) of 80% , subject to α=5.
Data exclusions Tumor-bearing mice were enrolled for study if tumors reached 5mm diameter at day 10 post-implantation. Tumors that implanted intraperitoneally prior to commencing treatment on day 10 were censored. Tumors demonstrating severe ulceration were censored from flow cytometric endpoint analysis.
Replication
All attempts at replication were successful. Experiments were reproduced in at least two independent experiments as indicated.
Randomization For in vivo studies, mice were stratified by gender and block randomized for tumor implantation and treatment.
Blinding
Investigators were not blinded to most studies as interventions required knowledge of the individual experimental groups. To establish objective measurements from studies incorporating immunohistochemistry and immunofluorescent microscopy, multiple random fields were collected per replicate, and cell counts in each field were averaged for every biological replicate."
Reporting for specific materials, systems and methods Cell line source(s) Cancer Discovery 2016), which arose spontaneously in KrasLSL.G12D/+; Trp53R172H/+; Pdx-Cre mice were backcrossed >10 generations onto the C57Bl/6 background. For genetic studies, isogenic clones from these lines were used to minimize intratumoral heterogeneity.
Authentication
Tumor cell lines were authenticated to be syngeneic with the C57BL/6 background using DartMouse sequencing.
Mycoplasma contamination
Tumor cell lines were routinely tested for mycoplasma using MycoAlert (Cambrex).
Commonly misidentified lines (See ICLAC register)
No commonly misidentified cell lines were used.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals C57BL/6 mice were obtained from Jackson Laboratories and were bred at the University of Pennsylvania. Male and female C57BL/6 mice aged between 9-16 weeks were enrolled in studies or used for derivation of bone marrow macrophages. Tumor bearing male and female KPC mice (KrasLSL.G12D/+; Trp53R172H/+; Pdx-Cre mice backcrossed onto the C57Bl/6 background) were age and gender matched with Pdx-Cre mice for analysis.
Wild animals N/A
Field-collected samples N/A
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
Deatails regarding the biological source of cells and tissue processing steps are describes in the Methods. Specifically, pancreatic tumor cell cultures were treated with trypsin and prepared as a single-cell suspension for flow cytometric analysis; murine macrophages in culture were incubated in cell dissociation buffer prior to mechanical detachment and resuspension. For intracellular stains, cells were permeabilized in 0.1% Triton-X for 15 min. For tumors, samples were harvested upon necropsy, mechanically separated, and digested in 1 mg/ml collagenase and 100 μUnits/ml DNase I. Tumor digests were filtered and resuspended as single cell suspensions. Cells were treated with Fc-block, then stained with Amcyan live/dead dye.
Instrument FACS Canto (BD Biosciences)
Software Samples were collected using FACSDiva software (v8.0.1) and analysis was performed using FlowJo (v10. 3) Cell population abundance Following CRISPR-deletion in an isogenic line, CD47+ and CD47-cells sorted from populations treated with control or CD47targeting guide RNA resulted in post-sort fractions that were respectively 95-100% CD47+ and CD47-. Following GFP-labeling, sorting for GFP+ cells in CD47+ and CD47-populations resulted in comparable 95+% GFP+ populations.
Gating strategy
Gating strategies are described in supplementary figures 4 and 5. Specifically, singlet cells were gated on using FSC-H versus FSC-A, and live cells were identified by exclusion of AmCyan Live/Dead stain. Additional gating was based on thresholds from staining of FMO and isotype antibody when possible.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
